JP2016041071A5 - - Google Patents

Download PDF

Info

Publication number
JP2016041071A5
JP2016041071A5 JP2015204285A JP2015204285A JP2016041071A5 JP 2016041071 A5 JP2016041071 A5 JP 2016041071A5 JP 2015204285 A JP2015204285 A JP 2015204285A JP 2015204285 A JP2015204285 A JP 2015204285A JP 2016041071 A5 JP2016041071 A5 JP 2016041071A5
Authority
JP
Japan
Prior art keywords
expression level
patient
beneficial response
gbp1
rna transcript
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015204285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016041071A (ja
JP6190434B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016041071A publication Critical patent/JP2016041071A/ja
Publication of JP2016041071A5 publication Critical patent/JP2016041071A5/ja
Application granted granted Critical
Publication of JP6190434B2 publication Critical patent/JP6190434B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2015204285A 2004-04-09 2015-10-16 化学療法剤に対する応答を予測するための遺伝子発現マーカー Expired - Lifetime JP6190434B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56103504P 2004-04-09 2004-04-09
US60/561,035 2004-04-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013103045A Division JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Publications (3)

Publication Number Publication Date
JP2016041071A JP2016041071A (ja) 2016-03-31
JP2016041071A5 true JP2016041071A5 (enExample) 2016-09-08
JP6190434B2 JP6190434B2 (ja) 2017-08-30

Family

ID=34981928

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007507495A Expired - Lifetime JP5813908B2 (ja) 2004-04-09 2005-04-07 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2013103045A Expired - Lifetime JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2015204285A Expired - Lifetime JP6190434B2 (ja) 2004-04-09 2015-10-16 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007507495A Expired - Lifetime JP5813908B2 (ja) 2004-04-09 2005-04-07 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2013103045A Expired - Lifetime JP6130726B2 (ja) 2004-04-09 2013-05-15 化学療法剤に対する応答を予測するための遺伝子発現マーカー

Country Status (9)

Country Link
US (2) US7871769B2 (enExample)
EP (4) EP1737980A2 (enExample)
JP (3) JP5813908B2 (enExample)
AU (2) AU2005233593B2 (enExample)
CA (2) CA2563074C (enExample)
DK (1) DK2163650T3 (enExample)
ES (2) ES2550614T3 (enExample)
IL (4) IL178508A (enExample)
WO (1) WO2005100606A2 (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
WO2006052731A2 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CN102605066A (zh) * 2004-12-08 2012-07-25 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
US8133692B2 (en) * 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
WO2007015947A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
JP5984324B2 (ja) * 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
JP2008017832A (ja) * 2006-06-13 2008-01-31 Sysmex Corp がんの転移の判定方法及び判定装置
ES2405654T3 (es) * 2006-09-21 2013-05-31 Nuclea Biomarkers Llc Perfiles de expresión asociados con el tratamiento con irinotecan
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
US8232085B2 (en) * 2007-03-14 2012-07-31 Bionsil S.R.L. Isoform of bruton's tyrosine kinase (BTK) protein
US20090258795A1 (en) * 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
WO2009026128A2 (en) * 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
JP2009050189A (ja) * 2007-08-24 2009-03-12 Sumitomo Bakelite Co Ltd 抗癌剤の有効性予測方法
CA2699385A1 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
JP5303132B2 (ja) * 2007-09-20 2013-10-02 シスメックス株式会社 がん細胞の存否を判定する方法及び装置
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
CN101910414B (zh) 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
EP2304047A4 (en) * 2008-05-07 2012-12-26 Eutropics Pharmaceuticals Inc ANTIBODIES TAKEN UPON HETERODIMES OF THE BCL-2 FAMILY AND THEIR USES
CA2723972A1 (en) 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
WO2010007083A2 (en) * 2008-07-15 2010-01-21 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
KR100996994B1 (ko) * 2008-08-18 2010-11-25 울산대학교 산학협력단 간세포암종 수술후 재발 또는 재발 발병 위험성의 진단방법
JP2012500631A (ja) * 2008-08-20 2012-01-12 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド， ア ボディー コーポレイト Ｉｇｆ−１ｒ処置に対する癌の感受性を評価するためのマーカー
JP2010057486A (ja) * 2008-09-02 2010-03-18 Sysmex Corp 化学療法に対するがん患者の応答の予測方法
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
JP2012511323A (ja) * 2008-12-10 2012-05-24 イプソゲン 腫瘍中のｅｒｂｂ２の変化を特定するための方法
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9279157B2 (en) * 2009-02-06 2016-03-08 The Regents Of The University Of California EMX2 in cancer diagnosis and prognosis
US8972899B2 (en) 2009-02-10 2015-03-03 Ayasdi, Inc. Systems and methods for visualization of data analysis
US20130144916A1 (en) * 2009-02-10 2013-06-06 Ayasdi, Inc. Systems and Methods for Mapping New Patient Information to Historic Outcomes for Treatment Assistance
CA2758523C (en) * 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
US20130203059A1 (en) * 2010-07-02 2013-08-08 Topogen, Inc. Method for Diagnosis of Bladder Cancer and Related Kits
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
TW201209163A (en) * 2010-07-12 2012-03-01 Opko Curna Llc Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
CN103228798B (zh) 2010-09-24 2015-12-09 斯坦福大学托管董事会 使用固定的引物直接捕获、扩增及测序靶标dna
SI2619576T1 (sl) 2010-09-24 2021-03-31 Niels Grabe Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
JP5828446B2 (ja) * 2011-02-10 2015-12-09 国立大学法人秋田大学 扁平上皮癌組織の放射線感受性マーカー
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
US20130042333A1 (en) * 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
EA025926B1 (ru) * 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
WO2012174203A2 (en) * 2011-06-14 2012-12-20 Anthony Albino Methods and kits for the detection and treatment of recurring prostate cancer
WO2013050998A1 (en) * 2011-10-04 2013-04-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cd247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
CA2857505A1 (en) * 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US10519506B2 (en) 2011-12-22 2019-12-31 Baylor Research Institute Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer
WO2013109690A1 (en) * 2012-01-17 2013-07-25 Myriad Genetics, Inc. Breast cancer prognosis signatures
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
FR2987446B1 (fr) * 2012-02-28 2016-01-01 Univ Nice Sophia Antipolis Test diagnostic de la resistance a l'azacitidine
WO2013170174A1 (en) 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
IN2014DN11205A (enExample) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US20140315844A1 (en) * 2012-11-30 2014-10-23 Celera Corporation Multi-gene signatures for predicting response to chemotherapy or risk of metastasis for breast cancer
AU2013353839A1 (en) 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer
US10240206B2 (en) * 2013-02-01 2019-03-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Biomarkers and methods for predicting benefit of adjuvant chemotherapy
US10041125B2 (en) 2013-03-15 2018-08-07 Janssen Pharmaceutica Nv Assay for predictive biomarkers
US10181008B2 (en) * 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
PT3134119T (pt) * 2014-04-24 2018-11-07 Pfizer Tratamento do cancro
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN104004844A (zh) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 乳腺癌21基因联合检测试剂盒及其制备方法
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
ES2857953T3 (es) 2014-10-24 2021-09-29 Koninklijke Philips Nv Pronóstico médico y predicción de la respuesta al tratamiento usando las actividades de múltiples rutas de señalización celular
EP3210144B1 (en) 2014-10-24 2020-10-21 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
EP3245301B1 (en) 2015-01-12 2020-11-11 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
EP3248127A4 (en) 2015-01-20 2018-08-08 Nantomics, LLC Systems and methods for response prediction to chemotherapy in high grade bladder cancer
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
CA3008002A1 (en) * 2015-12-10 2017-06-15 Nantomics, Llc Integrated analysis to determine prognosis after treatment for primary breast cancer
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
SG10202008771WA (en) 2016-09-16 2020-10-29 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018165532A1 (en) 2017-03-10 2018-09-13 Baylor Research Institute Methods for diagnosing and treating gastric cancer using mirna expression
SG11201909336VA (en) * 2017-04-19 2019-11-28 Bio Path Holdings Inc P-ethoxy nucleic acids for stat3 inhibition
EP3612160A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS TO INHIBIT BCL2
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US12497660B2 (en) 2017-08-04 2025-12-16 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
RU2675236C1 (ru) * 2018-02-22 2018-12-18 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития метастазов у больных раком молочной железы
KR102767594B1 (ko) * 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
US20220357328A1 (en) * 2019-09-09 2022-11-10 Oaklabs Gmbh Superior biomarker signature to predict the response of a breast cancer patient to chemotherapy
CN111184865B (zh) * 2020-03-09 2021-11-16 复旦大学附属金山医院 Stat1在耐紫杉醇上皮性卵巢癌治疗中的用途
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
EP4623092A1 (en) * 2022-11-21 2025-10-01 Merck Sharp & Dohme LLC Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease
WO2025171441A1 (en) * 2024-02-13 2025-08-21 The Council Of The Queensland Institute Of Medical Research Prognostic signature for cancer recurrence and responsiveness

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5962312A (en) 1995-12-18 1999-10-05 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
KR100645448B1 (ko) 1996-11-20 2006-11-13 예일 유니버시티 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
US6331396B1 (en) 1998-09-23 2001-12-18 The Cleveland Clinic Foundation Arrays for identifying agents which mimic or inhibit the activity of interferons
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
DE19922052A1 (de) 1999-05-14 2000-11-16 Theragen Molekularmedizinische Verfahren zum Nachweis der Wirkung von unterschiedlichen Chemotherapeutika und/oder einer Strahlentherapie bei malignen Erkrankungen sowie Verfahren zur Auswahl wirkungsvoller therapeutischer Mittel zu deren Therapie
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
CA2391805A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051661A2 (en) 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
EP1257664A4 (en) 2000-01-28 2006-04-05 Althea Technologies Inc METHOD FOR THE ANALYSIS OF GENE EXPRESSION
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
WO2001075159A2 (en) 2000-03-31 2001-10-11 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001280008A1 (en) 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
AU2001278076A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
WO2002010436A2 (en) 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AU2002234799A1 (en) 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7097966B2 (en) 2001-01-12 2006-08-29 Yale University Detection of survivin in the biological fluids of cancer patients
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
CA2440703A1 (en) 2001-01-24 2002-08-01 Protein Design Labs, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
CA2439779A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
EP1373896A2 (en) 2001-03-12 2004-01-02 MonoGen, Inc. Cell-based detection and differentiation of disease states
US20030077582A1 (en) * 2001-03-27 2003-04-24 Wen-Lin Kuo Methods for diagnosing and monitoring malignancies by screeining gene copy numbers
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US20040009489A1 (en) 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US20030124130A1 (en) * 2002-01-02 2003-07-03 Brown Robert E. Proteomic analysis of tumors for development of consultative report of therapeutic options
WO2003057916A2 (en) * 2002-01-09 2003-07-17 Riken Cancer profiles
US7704700B2 (en) * 2002-02-12 2010-04-27 Burnham Institute For Medical Research Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
DK3115470T3 (en) 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20050216961A1 (en) 2002-03-28 2005-09-29 Delaney Allen D Cancer associated protein kinases and their uses
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US7767391B2 (en) 2003-02-20 2010-08-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
AU2005245815B2 (en) 2004-05-07 2011-06-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CA2569202A1 (en) * 2004-05-28 2005-12-15 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006052731A2 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
NZ593224A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (fap) for colorectal cancer prognosis
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009026128A2 (en) 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
CA2723972A1 (en) 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
US8877445B2 (en) 2008-11-14 2014-11-04 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
JP5964752B2 (ja) 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法

Similar Documents

Publication Publication Date Title
JP2016041071A5 (enExample)
Khan et al. MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer
Nassar et al. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction
Kachalaki et al. Cancer chemoresistance; biochemical and molecular aspects: a brief overview
JP2016174600A5 (enExample)
JP2017055769A5 (enExample)
Hoppe et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
BR112012024718A2 (pt) método para a predição da recorrência de câncer da mama sob tratamento endócrino
JP2007507222A5 (enExample)
JP2010538609A5 (enExample)
WO2016172710A3 (en) Methods and reagents for determination and treatment of organotropic metastasis
WO2016036994A8 (en) Method of analysis allowing avoidance of surgery
WO2013098797A3 (en) Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
RU2017125053A (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
JP2016521979A5 (enExample)
WO2016203262A3 (en) Gene signatures predictive of metastatic disease
Su et al. Antrodia cinnamomea sensitizes radio-/chemo-therapy of cancer stem-like cells by modulating microRNA expression
JP2017536085A5 (enExample)
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
WO2017044694A3 (en) Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis
Nikolova et al. 52P MiRNA profile associated with the invasiveness in non-functioning pituitary adenomas
Wang et al. The Long Noncoding RNA SPRY4-IT1 Contributes to proliferation of Human breast cancer Cells via upregualtion of ZNF703 Expression
Dai et al. Machine learning models for predicting lymph node and distant metastases in colorectal cancer
Albain et al. Proceedings of the first global workshop on breast cancer: Pathways to the evaluation and clinical development of novel agents for breast cancer